Last $2.67 USD
Change Today -0.09 / -3.26%
Volume 535.9K
As of 8:10 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

cytrx corp (CYTR) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/14 - $8.35
52 Week Low
11/7/13 - $2.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CYTRX CORP (CYTR)

Related News

No related news articles were found.

cytrx corp (CYTR) Related Businessweek News

No Related Businessweek News Found

cytrx corp (CYTR) Details

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate includes aldoxorubicin that has completed Phase IIb clinical trial as a first-line therapy for soft tissue sarcomas; and has initiated an international Phase II clinical trial in patients with late-stage glioblastoma multiforme, and a Phase II clinical trial in HIV-related Kaposi’s sarcoma. It also develops aldoxorubicin, which is in Phase Ib/II clinical trial primarily in the same indication, a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and is in Phase IIb pharmacokinetics clinical trial in patients with metastatic solid tumors. In addition, the company has evaluated a drug candidate bafetinib, in the ENABLE Phase II clinical trial in high-risk B-cell chronic lymphocytic leukemia. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

cytrx corp (CYTR) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $450.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $825.0K
Senior Vice President of Legal Affairs, Gener...
Total Annual Compensation: $500.0K
Senior Vice President of Drug Development
Total Annual Compensation: $450.0K
Compensation as of Fiscal Year 2013.

cytrx corp (CYTR) Key Developments

CytRx Corporation Announces Publication of Phase 1b/2 Aldoxorubicin Clinical Data in Soft Tissue Sarcoma in Cancer

CytRx Corporation (CYTR) announced that a paper, titled 'A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma', has been published online in Cancer, peer-reviewed journal of the American Cancer Society. The paper discusses results from CytRx's completed Phase 1b/2 clinical trial where 25 patients were enrolled, including 17 patients (68%) with advanced soft tissue sarcoma (STS). Data from the trial demonstrated that aldoxorubicin administered at its maximum tolerated dose (MTD) of 350mg/m(2) showed a substantial increase in median progression-free survival (PFS) in patients with advanced STS (n=13). Partial responses (PR) were achieved in 38% of patients and stable disease (SD) was achieved in 46% of patients. Median PFS was 11.25 months and median overall survival (OS) was 21.71 months. Notably, 12 of the 13 patients in the MTD dosing cohort had received prior chemotherapy and had experienced either no response or disease progression while on prior therapy. In addition, patients in this dosing cohort completed a median of 8 dosing cycles, and 9 patients (69%) had a PR or SD lasting >=4 months. Aldoxorubicin was generally well tolerated, with no clinically significant cardiotoxicities and no drug-related deaths. Aldoxorubicin is currently being studied in a pivotal global Phase 3 clinical trial evaluating the efficacy and safety of aldoxorubicin as a second-line treatment for patients with STS under a Special Protocol Assessment with the FDA. CytRx is also evaluating aldoxorubicin in two Phase 2 clinical trials, one in patients with late-stage glioblastoma (GBM) and the other in HIV-related Kaposi's sarcoma, a global Phase 2b clinical trial in patients with relapsed small cell lung cancer, a Phase 1b trial in combination with ifosfamide in patients with soft tissue sarcoma, and a Phase 1b trial in combination with gemcitabine in patients with metastatic solid tumors.

CytRx Corporation Appoints Steven A. Kriegsman as Chairman of the Board

CytRx Corporation announced that its board of directors has appointed Steven A. Kriegsman, President, Chief Executive Officer and a Director of the Company, as chairman of the board, effective October 15, 2014. He replaces Max E. Link, Ph.D. whose unexpected passing was announced on October 7, 2014.

CytRx Launches Discovery Laboratory to Develop Albumin-Binding Anti-Cancer Drug Platform

CytRx Corporation announced that it has commenced operations at its new discovery laboratory, located in Freiburg, Germany. The new laboratory will conduct discovery and translational research to create drug candidates that utilize novel linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors. Led by Felix Kratz, Ph.D., Vice President of Drug Discovery and inventor of aldoxorubicin, and Andre Warnecke, Ph.D., Senior Director of Drug Discovery, the discovery team will work to expand CytRx's novel albumin-binding anti-cancer drug pipeline.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTR:US $2.67 USD -0.09

CYTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTR.
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,536.7x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 514.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTRX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at